Skip to main content

Advertisement

Springer Nature Link
Log in

Phosphate binders in chronic kidney disease: an updated narrative review of recent data

  • Review
  • Published:
Journal of Nephrology Aims and scope Submit manuscript

Abstract

Chronic kidney disease (CKD) is frequently accompanied by hyperphosphatemia. High serum phosphate usually requires dietary measures, adequate dialysis prescription and/or phosphate binders. For this narrative review a PubMed searched was undertaken to identify new publications on phosphate binders that had been published between January 2015 and July 2019. The present review summarizes this most recent information on dietary measures and their problems in treating hyperphosphatemia in CKD patients, overall effects of phosphate binders on cardiovascular mortality and morbidity, adherence to phosphate binder therapy as well as new data on specific aspects of the various phosphate binders on the market: calcium-containing phosphate binders, polymeric phosphate binders (sevelamer, bixalomer, colestilan), magnesium-containing phosphate binders, lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide, and new compounds in development, in particular drugs targeting intestinal phosphate transporters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Akizawa T, Origasa H, Kameoka C, Tsukada J, Kuroishi K, Yamaguchi Y (2016) Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial. Ther Apher Dial 20:588–597

    CAS  PubMed  Google Scholar 

  2. Akizawa T, Tsukada J, Kameoka C, Kuroishi K, Yamaguchi Y (2017) Long-term safety and efficacy of bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis. Ther Apher Dial 21:173–179

    CAS  PubMed  Google Scholar 

  3. Awad C, Gilkison K, Shaw E (2019) Lanthanum phosphate binder-induced iron deficiency anaemia. BMJ Case Rep 12:e226157

    PubMed  Google Scholar 

  4. Ban S, Suzuki S, Kubota K, Ohshima S, Satoh H, Imada H, Ueda Y (2017) Gastric mucosal status susceptible to lanthanum deposition in patients treated with dialysis and lanthanum carbonate. Ann Diagn Pathol 26:6–9

    PubMed  Google Scholar 

  5. Bhandari SK, Liu IA, Kujubu DA, Huynh T, Behayaa H, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ, Sim JJ (2017) Use of phosphorus binders among non-dialysis chronic kidney disease patients and mortality outcomes. Am J Nephrol 45:431–441

    CAS  PubMed  Google Scholar 

  6. Block GA, Block MS, Smits G, Mehta R, Isakova T, Wolf M, Chertow GM (2019) A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD. J Am Soc Nephrol 30:1495–1504

    PubMed  Google Scholar 

  7. Block GA, Pergola PE, Fishbane S, Martins JG, LeWinter RD, Uhlig K, Neylan JF, Chertow GM (2019) Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses. Nephrol Dial Transplant 34:1115–1124

    PubMed  Google Scholar 

  8. Cataldo E, Columbano V, Nielsen L, Gendrot L, Covella B, Piccoli GB (2018) Phosphate binders as a cause of hypothyroidism in dialysis patients: practical indications from a review of the literature. BMC Nephrol 19:155

    PubMed  PubMed Central  Google Scholar 

  9. Chertow GM, Block GA, Neylan JF, Pergola PE, Uhlig K, Fishbane S (2017) Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease. PLoS One 12:e0188712

    PubMed  PubMed Central  Google Scholar 

  10. Covic AC, Floege J, Ketteler M, Sprague SM, Lisk L, Rakov V, Rastogi A (2017) Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant 32:1330–1338

    PubMed  Google Scholar 

  11. Coyne DW, Ficociello LH, Parameswaran V, Anderson L, Vemula S, Ofsthun NJ, Mullon C, Maddux FW, Kossmann RJ, Sprague SM (2017) Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: a retrospective analysis of pharmacy data. Clin Nephrol 88:59–67

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Diaz-Tocados JM, Peralta-Ramirez A, Rodriguez-Ortiz ME, Raya AI, Lopez I, Pineda C, Herencia C, Montes de Oca A, Vergara N, Steppan S, Pendon-Ruiz de Mier MV, Buendia P, Carmona A, Carracedo J, Alcala-Diaz JF, Frazao J, Martinez-Moreno JM, Canalejo A, Felsenfeld A, Rodriguez M, Aguilera-Tejero E, Almaden Y, Munoz-Castaneda JR (2017) Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats. Kidney Int 92:1084–1099

    CAS  PubMed  Google Scholar 

  13. Duff EA, Chawke FM (2017) A service review to assess if innovative intensive phosphate dietary education can help reduce phosphate levels to the recommended range in a hemodialysis population. Hemodial Int 21(Suppl 2):S22–S26

    PubMed  Google Scholar 

  14. El Borolossy R, El Wakeel LM, El Hakim I, Sabri N (2016) Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis. Pediatr Nephrol 31:289–296

    PubMed  Google Scholar 

  15. Evsanaa B, Liu I, Aliazardeh B, Mahdavi S, Bajwa G, Gula J, Tam M, Sze E, Roscoe JM, Tam PY, Sikaneta T (2015) MgCaCO3 versus CaCO3 in peritoneal dialysis patients–a cross-over pilot trial. Perit Dial Int 35:31–34

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Fissell RB, Karaboyas A, Bieber BA, Sen A, Li Y, Lopes AA, Akiba T, Bommer J, Ethier J, Jadoul M, Pisoni RL, Robinson BM, Tentori F (2016) Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS. Hemodial Int 20:38–49

    PubMed  Google Scholar 

  17. Floege J (2016) Phosphate binders in chronic kidney disease: a systematic review of recent data. J Nephrol 29:329–340

    CAS  PubMed  Google Scholar 

  18. Floege J, Covic AC, Ketteler M, Mann J, Rastogi A, Spinowitz B, Rakov V, Lisk LJ, Sprague SM (2017) One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol Dial Transplant 32:1918–1926

    CAS  PubMed  Google Scholar 

  19. Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM, Group PAS (2014) A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 86:638–647

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Fujii H, Kono K, Nakai K, Goto S, Nishii T, Kono A, Nishi S (2018) Effects of lanthanum carbonate on coronary artery calcification and cardiac abnormalities after initiating hemodialysis. Calcif Tissue Int 102:310–320

    CAS  PubMed  Google Scholar 

  21. Gao Y, Wang G, Li Y, Lv C, Wang Z (2019) Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3–4 chronic kidney disease. J Nephrol 32:265–272

    CAS  PubMed  Google Scholar 

  22. Goto K, Goto S, Fujii H, Watanabe K, Kono K, Nishi S (2019) Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients. J Bone Miner Metab 37:1075–1082

    CAS  PubMed  Google Scholar 

  23. Hain DJ, Marinaro M, Koeper DW, Rosenthal MA, Chillemi S, Huffman JM, Gerbeling T, Pritsiolas JM, Loram LC, Pergola PE (2017) Ferric citrate controls serum phosphorus in dialysis patients: retrospective data. Clin Nephrol 88:12–18

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Haratake J, Yasunaga C, Ootani A, Shimajiri S, Matsuyama A, Hisaoka M (2015) Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. Am J Surg Pathol 39:767–771

    PubMed  Google Scholar 

  25. Hattori K, Maeda T, Nishida S, Imanishi M, Sakaguchi M, Amari Y, Moriya T, Hirose Y (2017) Correlation of lanthanum dosage with lanthanum deposition in the gastroduodenal mucosa of dialysis patients. Pathol Int 67:447–452

    CAS  PubMed  Google Scholar 

  26. Hertel J, Locatelli F, Spasovski G, Dimkovic N, Wanner C (2015) Randomized, double-blind, placebo-controlled, withdrawal study of colestilan after dose titration in chronic kidney disease dialysis patients with hyperphosphatemia. Nephron 130:229–238

    CAS  PubMed  Google Scholar 

  27. Hjemas BJ, Bovre K, Mathiesen L, Lindstrom JC, Bjerknes K (2019) Interventional study to improve adherence to phosphate binder treatment in dialysis patients. BMC Nephrol 20:178

    PubMed  PubMed Central  Google Scholar 

  28. Hoda RS, Sanyal S, Abraham JL, Everett JM, Hundemer GL, Yee E, Lauwers GY, Tolkoff-Rubin N, Misdraji J (2017) Lanthanum deposition from oral lanthanum carbonate in the upper gastrointestinal tract. Histopathology 70:1072–1078

    PubMed  PubMed Central  Google Scholar 

  29. Hood CJ, Wolley MJ, Kam AL, Kendrik-Jones JC, Marshall MR (2015) Feasibility study of colestipol as an oral phosphate binder in hemodialysis patients. Nephrology (Carlton) 20:250–256

    CAS  Google Scholar 

  30. Hutchison A, Whelton A, Thadhani R, Achenbach H, Vergani A, Wu J, Hall G (2018) Long-term mortality and bone safety in patients with end-stage renal disease receiving lanthanum carbonate. Nephron 140:265–274

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Hutchison AJ, Wilson RJ, Garafola S, Copley JB (2016) Lanthanum carbonate: safety data after 10 years. Nephrology (Carlton) 21:987–994

    CAS  Google Scholar 

  32. Imtiaz R, Atkinson K, Guerinet J, Wilson K, Leidecker J, Zimmerman D (2017) A pilot study of OkKidney, a phosphate counting application in patients on peritoneal dialysis. Perit Dial Int 37:613–618

    PubMed  Google Scholar 

  33. Iwamuro M, Urata H, Tanaka T, Kawano S, Kawahara Y, Kimoto K, Okada H (2018) Lanthanum deposition corresponds to white lesions in the stomach. Pathol Res Pract 214:934–939

    CAS  PubMed  Google Scholar 

  34. Iwamuro M, Urata H, Tanaka T, Kawano S, Kawahara Y, Kimoto K, Okada H (2018) Lanthanum deposition in the stomach in the absence of Helicobacter pylori infection. Intern Med 57:801–806

    PubMed  Google Scholar 

  35. Iwamuro M, Urata H, Tanaka T, Kawano S, Kawahara Y, Okada H (2019) Frequent involvement of the duodenum with lanthanum deposition: a retrospective observational study. Intern Med 58(16):2283–2289. https://doi.org/10.2169/internalmedicine.2398-18

    Article  PubMed  PubMed Central  Google Scholar 

  36. Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M (2019) Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: the COMBINE trial. J Am Soc Nephrol 30:1096–1108

    PubMed  Google Scholar 

  37. Jalal D, McFadden M, Dwyer JP, Umanath K, Aguilar E, Yagil Y, Greco B, Sika M, Lewis JB, Greene T, Goral S (2017) Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis. Hemodial Int 21:243–249

    PubMed  Google Scholar 

  38. Jansz TT, Neradova A, van Ballegooijen AJ, Verhaar MC, Vervloet MG, Schurgers LJ, van Jaarsveld BC (2018) The role of kidney transplantation and phosphate binder use in vitamin K status. PLoS One 13:e0203157

    PubMed  PubMed Central  Google Scholar 

  39. Kalantar-Zadeh K, Parameswaran V, Ficociello LH, Anderson L, Ofsthun NJ, Kwoh C, Mullon C, Kossmann RJ, Coyne DW (2018) Real-world scenario improvements in serum phosphorus levels and pill burden in peritoneal dialysis patients treated with sucroferric oxyhydroxide. Am J Nephrol 47:153–161

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Keith M, de Sequera P, Clair F, Pedersini R (2016) Lanthanum carbonate oral powder: satisfaction, preference and adherence in French and Spanish patients with end-stage renal disease. Drugs Context 5:212300

    PubMed  PubMed Central  Google Scholar 

  41. Kendrick J, Parameswaran V, Ficociello LH, Ofsthun NJ, Davis S, Mullon C, Kossmann RJ, Kalantar-Zadeh K (2019) One-year historical cohort study of the phosphate binder sucroferric oxyhydroxide in patients on maintenance hemodialysis. J Ren Nutr 29(5):428–437. https://doi.org/10.1053/j.jrn.2018.11.002

    Article  CAS  PubMed  Google Scholar 

  42. Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, Walpen S, Floege J (2019) Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant 34:1163–1170

    PubMed  Google Scholar 

  43. Kim J, Olson K, Butani L (2016) Sevelamer crystals in the mucosa of the gastrointestinal tract in a teenager with end-stage renal disease. Pediatr Nephrol 31:339–341

    PubMed  Google Scholar 

  44. Koiwa F, Yokoyama K, Fukagawa M, Akizawa T (2018) Efficacy and safety of sucroferric oxyhydroxide and calcium carbonate in hemodialysis patients. Kidney Int Rep 3:185–192

    PubMed  Google Scholar 

  45. Koiwa F, Yokoyama K, Fukagawa M, Akizawa T (2017) Long-term assessment of the safety and efficacy of PA21 (sucroferric oxyhydroxide) in Japanese hemodialysis patients with hyperphosphatemia: an open-label, multicenter, phase III study. J Ren Nutr 27:346–354

    CAS  PubMed  Google Scholar 

  46. Koiwa F, Yokoyama K, Fukagawa M, Terao A, Akizawa T (2017) Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open-label, multicentre, 12-week phase III study. Nephrology (Carlton) 22:293–300

    CAS  Google Scholar 

  47. Komaba H, Kakuta T, Wada T, Hida M, Suga T, Fukagawa M (2019) Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate. Nephrol Dial Transplant 34:318–325

    CAS  PubMed  Google Scholar 

  48. Komaba H, Wang M, Taniguchi M, Yamamoto S, Nomura T, Schaubel DE, Smith AR, Zee J, Karaboyas A, Bieber B, Fukagawa M, Tentori F (2017) Initiation of sevelamer and mortality among hemodialysis patients treated with calcium-based phosphate binders. Clin J Am Soc Nephrol 12:1489–1497

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Kovesdy CP, Lu JL, Wall BM, Gyamlani G, Naseer A, Wallick A, Han Z, Thomas F, Quarles LD, Jarmukli N (2018) Changes with lanthanum carbonate, calcium acetate, and phosphorus restriction in CKD: a randomized controlled trial. Kidney Int Rep 3:897–904

    PubMed  PubMed Central  Google Scholar 

  50. Lenglet A, Liabeuf S, El Esper N, Brisset S, Mansour J, Lemaire-Hurtel AS, Mary A, Brazier M, Kamel S, Mentaverri R, Choukroun G, Fournier A, Massy ZA (2017) Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant 32:870–879

    CAS  PubMed  Google Scholar 

  51. Liabeuf S, Ryckelynck JP, El Esper N, Urena P, Combe C, Dussol B, Fouque D, Vanhille P, Frimat L, Thervet E, Mentaverri R, Prie D, Choukroun G, Collaborators FS (2017) Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD. Clin J Am Soc Nephrol 12:1930–1940

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Lioufas N, Toussaint ND, Pedagogos E, Elder G, Badve SV, Pascoe E, Valks A, Hawley C, Committee I-CW (2019) Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study. BMJ Open 9:e024382

    PubMed  PubMed Central  Google Scholar 

  53. Liu Z, Su G, Guo X, Wu Y, Liu X, Zou C, Zhang L, Yang Q, Xu Y, Ma W (2015) Dietary interventions for mineral and bone disorder in people with chronic kidney disease. Cochrane Database Syst Rev 9:CD010350

    Google Scholar 

  54. Locatelli F, Dimkovic N, Spasovski G (2015) Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Expert Rev Endocrinol Metab 10:131–142

    CAS  PubMed  Google Scholar 

  55. Locatelli F, Spasovski G, Dimkovic N, Wanner C (2016) Long-term evaluation of colestilan in chronic kidney disease stage 5 dialysis patients with hyperphosphataemia. Blood Purif 41:247–253

    CAS  PubMed  Google Scholar 

  56. Lung YF, Sun YS, Lin CK, Uan JY, Huang HH (2016) Synthesis of Mg–Fe–Cl hydrotalcite-like nanoplatelets as an oral phosphate binder: evaluations of phosphorus intercalation activity and cellular cytotoxicity. Sci Rep 6:32458

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Maruyama N, Otsuki T, Yoshida Y, Nagura C, Kitai M, Shibahara N, Tomita H, Maruyama T, Abe M (2018) Ferric citrate decreases fibroblast growth factor 23 and improves erythropoietin responsiveness in hemodialysis patients. Am J Nephrol 47:406–414

    CAS  PubMed  Google Scholar 

  58. Matias PJ, Jorge C, Azevedo A, Laranjinha I, Navarro D, Mendes M, Amaral T, Ferreira C, Aires I, Gil C, Stuard S, Ferreira A (2016) Calcium acetate/magnesium carbonate and cardiovascular risk factors in chronic hemodialysis patients. Nephron 132:317–326

    CAS  PubMed  Google Scholar 

  59. Nagano N, Minegishi A, Ito K, Ando T, Tsutsui T, Ogawa T (2018) Phosphate binders derived from natural ores contain many kinds of metallic elements besides their active ingredient metals. Ther Apher Dial 22:630–634

    CAS  PubMed  Google Scholar 

  60. Nambiar S, Pillai UK, Devasahayam J, Oliver T, Karippot A (2018) Colonic mucosal ulceration and gastrointestinal bleeding associated with sevelamer crystal deposition in a patient with end stage renal disease. Case Rep Nephrol 2018:4708068

    PubMed  PubMed Central  Google Scholar 

  61. Neradova A, Schumacher SP, Hubeek I, Lux P, Schurgers LJ, Vervloet MG (2017) Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study. BMC Nephrol 18:149

    CAS  PubMed  PubMed Central  Google Scholar 

  62. Nguyen TM, Muller RH, Taupitz M, Schnorr J, Hamm B, Wagner S (2015) Novel oral phosphate binder with nanocrystalline maghemite-phosphate binding capacity and pH effect. Int J Pharm 482:21–26

    CAS  PubMed  Google Scholar 

  63. Otsuki T, Utsunomiya K, Moriuchi M, Horikoshi S, Okamura M, Suzuki H, Okamura M, Maruyama N, Shibahara N, Abe M (2018) Effect of sucroferric oxyhydroxide on fibroblast growth factor 23 levels in hemodialysis patients. Nephron 140:161–168

    CAS  PubMed  Google Scholar 

  64. Pai AB, Jang SM, Wegrzyn N (2016) Iron-based phosphate binders—a new element in management of hyperphosphatemia. Expert Opin Drug Metab Toxicol 12:115–127

    CAS  PubMed  Google Scholar 

  65. Palmer SC, Gardner S, Tonelli M, Mavridis D, Johnson DW, Craig JC, French R, Ruospo M, Strippoli GF (2016) Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials. Am J Kidney Dis 68:691–702

    CAS  PubMed  Google Scholar 

  66. Patel L, Bernard LM, Elder GJ (2016) Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol 11:232–244

    CAS  PubMed  Google Scholar 

  67. Rhee CM, You AS, Koontz Parsons T, Tortorici AR, Bross R, St-Jules DE, Jing J, Lee ML, Benner D, Kovesdy CP, Mehrotra R, Kopple JD, Kalantar-Zadeh K (2017) Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial. Nephrol Dial Transplant 32:1233–1243

    CAS  PubMed  Google Scholar 

  68. Ruggiero B, Trillini M, Tartaglione L, Rotondi S, Perticucci E, Tripepi R, Aparicio C, Lecchi V, Perna A, Peraro F, Villa D, Ferrari S, Cannata A, Mazzaferro S, Mallamaci F, Zoccali C, Bellasi A, Cozzolino M, Remuzzi G, Ruggenenti P, Kohan DE, ANSWER Study Organization (2019) Effects of sevelamer carbonate in patients with CKD and proteinuria: the ANSWER randomized trial. Am J Kidney Dis 74(3):338–350. https://doi.org/10.1053/j.ajkd.2019.01.029

  69. Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GF (2018) Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev 8:CD006023

    PubMed  Google Scholar 

  70. Russo D, Bellasi A, Pota A, Russo L, Di Iorio B (2015) Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease. J Nephrol 28:73–80

    CAS  PubMed  Google Scholar 

  71. Sherman RA (2016) Hyperphosphatemia in dialysis patients: beyond nonadherence to diet and binders. Am J Kidney Dis 67:182–186

    CAS  PubMed  Google Scholar 

  72. Spoendlin J, Paik JM, Tsacogianis T, Kim SC, Schneeweiss S, Desai RJ (2019) Cardiovascular outcomes of calcium-free vs calcium-based phosphate binders in patients 65 years or older with end-stage renal disease requiring hemodialysis. JAMA Intern Med 179(6):741–749. https://doi.org/10.1001/jamainternmed.2019.0045

    Article  PubMed  PubMed Central  Google Scholar 

  73. Sprague SM, Covic AC, Floege J, Ketteler M, Botha J, Chong EM, Rastogi A (2016) Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients. Am J Nephrol 44:104–112

    CAS  PubMed  Google Scholar 

  74. Sprague SM, Floege J (2018) Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Pharmacother 19:1137–1148

    CAS  PubMed  Google Scholar 

  75. Sprague SM, Ketteler M, Covic AC, Floege J, Rakov V, Walpen S, Rastogi A (2018) Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodial Int 22:480–491

    PubMed  Google Scholar 

  76. St Peter WL, Wazny LD, Weinhandl ED (2018) Phosphate-binder use in US dialysis patients: prevalence, costs, evidence, and policies. Am J Kidney Dis 71:246–253

    CAS  PubMed  Google Scholar 

  77. Taniguchi K, Kakuta H (2015) Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat. Eur J Pharmacol 766:129–134

    CAS  PubMed  Google Scholar 

  78. Tatsuzawa M, Ogawa R, Ohkubo A, Shimojima K, Maeda K, Echizen H, Miyazaki A (2016) Influence of proton pump inhibitors and histamine H2 receptor antagonists on serum phosphorus level control by calcium carbonate in patients undergoing hemodialysis: a retrospective medical chart review. J Pharm Health Care Sci 2:34

    PubMed  PubMed Central  Google Scholar 

  79. Thompson S, Manns B, Lloyd A, Hemmelgarn B, MacRae J, Klarenbach S, Unsworth L, Courtney M, Tonelli M (2017) Impact of using two dialyzers in parallel on phosphate clearance in hemodialysis patients: a randomized trial. Nephrol Dial Transplant 32:855–861

    CAS  PubMed  Google Scholar 

  80. Tieu C, Moreira RK, Song LM, Majumder S, Papadakis KA, Hogan MC (2016) A case report of sevelamer-associated recto-sigmoid ulcers. BMC Gastroenterol 16:20

    PubMed  PubMed Central  Google Scholar 

  81. Tsuchida K, Nagai K, Yokota N, Minakuchi J, Kawashima S (2016) Impact of lanthanum carbonate on prognosis of chronic hemodialysis patients: a retrospective cohort study (Kawashima Study). Ther Apher Dial 20:142–148

    CAS  PubMed  Google Scholar 

  82. Valika AK, Jain D, Jaffe PE, Moeckel G, Brewster UC (2016) A nodular foreign body reaction in a dialysis patient receiving long-term treatment with lanthanum carbonate. Am J Kidney Dis 67:128–132

    CAS  PubMed  Google Scholar 

  83. Vrdoljak I, Panjkota Krbavcic I, Bituh M, Leko N, Pavlovic D, Vrdoljak Margeta T (2017) The impact of education and cooking methods on serum phosphate levels in patients on hemodialysis: 1-year study. Hemodial Int 21:256–264

    PubMed  Google Scholar 

  84. Wald R, Rabbat CG, Girard L, Garg AX, Tennankore K, Tyrwhitt J, Smyth A, Rathe-Skafel A, Gao P, Mazzetti A, Bosch J, Yan AT, Parfrey P, Manns BJ, Walsh M (2017) Two phosphAte taRGets in End-stage renal disease Trial (TARGET): a randomized controlled trial. Clin J Am Soc Nephrol 12:965–973

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Wang F, Lu X, Zhang J, Xiong R, Li H, Wang S (2018) Effect of lanthanum carbonate on all-cause mortality in patients receiving maintenance hemodialysis: a meta-analysis of randomized controlled trials. Kidney Blood Press Res 43:536–544

    CAS  PubMed  Google Scholar 

  86. Wu-Wong JR, Chen YW, Wong JT, Wessale JL (2016) Preclinical studies of VS-505: a non-absorbable highly effective phosphate binder. Br J Pharmacol 173:2278–2289

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Yabuki K, Haratake J, Tsuda Y, Shiba E, Harada H, Yorita K, Uchihashi K, Matsuyama A, Hirata K, Hisaoka M (2018) Lanthanum-induced mucosal alterations in the stomach (lanthanum gastropathy): a comparative study using an animal model. Biol Trace Elem Res 185:36–47

    CAS  PubMed  Google Scholar 

  88. Yamaguchi T, Ohyama S, Furukawa H, Sato N, Ohnishi I, Kasashima S, Kawashima A, Kayahara M (2016) Sigmoid colon diverticula perforation associated with sevelamer hydrochloride administration: a case report. Ann Med Surg (Lond) 10:57–60

    Google Scholar 

  89. Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Ito K, Hanaki K, Wolf M, Hirakata H (2019) Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. Sci Rep 9:8877

    PubMed  PubMed Central  Google Scholar 

  90. Yuste C, Merida E, Hernandez E, Garcia-Santiago A, Rodriguez Y, Munoz T, Gomez GJ, Sevillano A, Praga M (2017) Gastrointestinal complications induced by sevelamer crystals. Clin Kidney J 10:539–544

    PubMed  PubMed Central  Google Scholar 

  91. Zhang C, Wang S, Zhao S, Zhang X (2017) Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: a prospective pilot study. Medicine (Baltimore) 96:e8664

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology and Clinical Immunology, University Hospital, Rheinisch Westfälische Technische Hochschule (RWTH), Pauwelsstr. 30, 52057, Aachen, Germany

    Jürgen Floege

Authors
  1. Jürgen Floege
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Jürgen Floege.

Ethics declarations

Conflict of interest

The author has received speaker honoraria and/or consultancy honoraria from Amgen, Chugai, Fresenius, Shire and Vifor.

Ethical statement

Does not apply.

Research involving human participants and/or animals

Does not apply.

Informed consent

Does not apply.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Floege, J. Phosphate binders in chronic kidney disease: an updated narrative review of recent data. J Nephrol 33, 497–508 (2020). https://doi.org/10.1007/s40620-019-00689-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40620-019-00689-w

Keywords